{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:57:55Z","timestamp":1791421075981,"version":"4.3.3"},"reference-count":116,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Applied Radiation and Isotopes"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1016\/s0969-8043(02)00192-6","type":"journal-article","created":{"date-parts":[[2002,10,10]],"date-time":"2002-10-10T17:33:13Z","timestamp":1034271193000},"page":"749-763","source":"Crossref","is-referenced-by-count":86,"title":["Radiolabeled peptides in the diagnosis and therapy of oncological diseases"],"prefix":"10.1016","volume":"57","author":[{"given":"Ronald E","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew L","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0969-8043(02)00192-6_BIB1","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0960-894X(98)00187-5","article-title":"Direct synthesis of [DOTA-D-Phe1-Tye3]-Octreotide (SMT487)","volume":"8","author":"Albert","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB2","first-page":"213","article-title":"64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors","volume":"42","author":"Anderson","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB3","first-page":"2002","article-title":"Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide","volume":"37","author":"Andersson","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB4","doi-asserted-by":"crossref","unstructured":"Argiris, A., Peccerillo, K., Murren, J.R., Cornelius, E., Modlin, I., 2000. Phase I\/II trial with 111In-pentetreotide in patients with advanced malignancies. Poster Presentation at the Digestive Disease Week 2000, Abstract 2748.","DOI":"10.1016\/S0016-5085(00)84188-8"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/bc9701959","article-title":"Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues","volume":"10","author":"Baidoo","year":"1998","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB6","first-page":"1134","article-title":"Procedure guideline for somatostatin receptor scintigraphy with 111In-pentetreotide","volume":"42","author":"Balon","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/bjc.1990.409","article-title":"A chelating derivative of alpha-melanocyte stimulating hormone as a potential imaging agent for malignant melanoma","volume":"62","author":"Bard","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s002590050241","article-title":"Targeting of cholecystokinin-B\/gastrin receptors in vivo","volume":"25","author":"Behr","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB9","first-page":"1029","article-title":"Radiolabeled peptides for targeting cholecystokinin-B\/gastrin receptor-expressing tumors","volume":"40","author":"Behr","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/00006231-200006000-00023","article-title":"Development of cholecystokinin-B\/gastrin-receptor binding peptides for diagnosis and therapy","volume":"21","author":"Behr","year":"2000","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB11","first-page":"157P","article-title":"Cholecystokinin (CCK)-B\/Gastrin-receptor binding peptides for diagnosis and therapy of metastatic medullary thyroid cancer","volume":"42","author":"Behr","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1378\/chest.115.1.224","article-title":"The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules","volume":"115","author":"Blum","year":"1999","journal-title":"Chest"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0959-8049(94)00467-J","article-title":"Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy","volume":"31A","author":"Bombardieri","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s002590050213","article-title":"Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans","volume":"25","author":"Breeman","year":"1998","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/(SICI)1097-0215(19991126)83:5<657::AID-IJC15>3.0.CO;2-Y","article-title":"Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy","volume":"83","author":"Breeman","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB16","first-page":"21P","article-title":"Optimizing conditions for radiolabeling DOTA-peptides","volume":"42","author":"Breeman","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00006231-200006000-00031","article-title":"Early experience with Y-90 lanreotide therapy","volume":"21","author":"Britton","year":"2000","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00006231-200006000-00033","article-title":"Treating disseminated NETs with high activity In-111 Octreotide","volume":"21","author":"Buscombe","year":"2000","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1021\/bc970031s","article-title":"Radiolabeling of epidermal growth factor with 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats","volume":"8","author":"Capala","year":"1997","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB20","unstructured":"CEA-Scan, 1996. Package insert. Immunomedics, Morris Plains."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB21","first-page":"1847","article-title":"Evaluation of an 111In-DOTA-Rhenium Cyclized \u03b1-MSH analog","volume":"42","author":"Chen","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB22","first-page":"111P","article-title":"Increasing tumor targeting capacity by peptide cyclization for 111In-DOTA-\u03b1-MSH analog","volume":"42","author":"Chen","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB23","first-page":"254P","article-title":"Optimization of the in vivo biological properties of 111In labeled DOTA-Rhenium cyclized \u03b1-MSH analogues","volume":"42","author":"Cheng","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB24","first-page":"18P","article-title":"90Y-DOTATOC treatment of patients with SSTR2 positive tumors","volume":"40","author":"Chinol","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB25","first-page":"18P","article-title":"In-111-octreotide therapy","volume":"40","author":"Cornelius","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB26","first-page":"2081","article-title":"Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog","volume":"40","author":"de Jong","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB27","first-page":"356","article-title":"Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues","volume":"43","author":"de Jong","year":"1999","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB28","first-page":"111P","article-title":"A radiolabeled cyclic RGD-DTPA-octreotate analog for tumor imaging and radionuclide therapy","volume":"42","author":"de Jong","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB29","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","article-title":"[177Lu-DOTA0,TYR3]octreotate for somatostatin receptor-targeted radionuclide therapy","volume":"92","author":"de Jong","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB30","series-title":"Radiolabeled Blood Elements","first-page":"195","article-title":"Peptides in biomedical sciences","author":"Dean","year":"1994"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB31","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00006231-199310000-00007","article-title":"Imaging of renal cell cancer with radiolabelled octreotide","volume":"14","author":"Flamen","year":"1993","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB32","first-page":"636","article-title":"111In-DTPA-D-Phe1 Octreotide binding and somatostatin receptor subtypes in thyroid tumors","volume":"41","author":"Forssell-Aronsson","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB33","first-page":"1191","article-title":"A modeling analysis of monoclonal antibody percolation through tumors","volume":"31","author":"Fujimori","year":"1990","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB34","first-page":"1S","article-title":"A tabulated summary of the FDG PET literature","volume":"42","author":"Gambhir","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB35","first-page":"369","article-title":"Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates","volume":"18","author":"Gansow","year":"1991","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s002590050504","article-title":"Cell irradiation caused by diagnostic nuclear medicine procedures","volume":"26","author":"Gardin","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB37","first-page":"539","article-title":"Specificity of somatostatin receptor scintigraphy","volume":"40","author":"Gibril","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00006231-200006000-00103","article-title":"90Y-DOTA-lanreotide","volume":"21","author":"Goldsmith","year":"2000","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB39","first-page":"326","article-title":"Glycosylated RGD-containing peptides","volume":"42","author":"Haubner","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB40","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/sj.onc.1204183","article-title":"Autocrine and paracrine signaling through neuropeptide receptors in human cancer","volume":"20","author":"Heasly","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB41","first-page":"274P","article-title":"111In\/90Y radiolabeled peptides for targeting prostate cancer; a matched pair gastrin releasing peptide (GRP) receptor localizing radiopharmaceutical","volume":"42","author":"Hoffman","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB42","first-page":"254P","article-title":"Development of a diagnostic radiopharmaceutical for visualization of primary and metastatic breast cancer","volume":"42","author":"Hoffman","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB43","first-page":"1256","article-title":"Progressive nuclear translocation of somatostatin analogs","volume":"41","author":"Hornick","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB44","first-page":"3039","article-title":"Transport of molecules in the tumor interstitium","volume":"47","author":"Jain","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB45","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Jan de Beur","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB46","first-page":"1514","article-title":"Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-Octreotide in patients with neuroendocrine tumors","volume":"41","author":"Janson","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB47","first-page":"126P","article-title":"Tumor targeting with radiolabeled integrin \u03b1v\u03b23 binding RGD peptides in a nude mouse tumor model","volume":"42","author":"Janssen","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000049168","article-title":"Somatostatin analogs in oncology","volume":"47","author":"Jenkins","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB50","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/bc980096a","article-title":"99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent","volume":"10","author":"Karra","year":"1999","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB51","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/BF02426696","article-title":"Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma","volume":"21","author":"Kirsch","year":"1994","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB52","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1] and [123I-Tyr3]-octreotide","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB53","doi-asserted-by":"crossref","unstructured":"Krenning, E.P., Kwekkeboom, D.J., Pauwels, S., et al., 1995. Somatostatin receptor scintigraphy. Nucl. Med. Ann. 1\u201350.","DOI":"10.1159\/000201398"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB54","first-page":"37P","article-title":"Long-term histological organ damage in animals following peptide receptor radionuclide therapy (PRRT) with high doses of 90Y- and 111In-labeled [DOTA0,TYR3]octreotide (DOTATOC)","volume":"42","author":"Krenning","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB55","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/0016-5085(93)91091-U","article-title":"Somatostatin-receptor imaging of human malignancies","volume":"105","author":"Kvols","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB56","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/BF00181066","article-title":"The value of Octreotide scintigraphy in patients with lung cancer","volume":"21","author":"Kwekkeboom","year":"1994","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB57","first-page":"1704","article-title":"Peptide receptor imaging and therapy","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB58","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTA0,Tyr3]octreotide","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogs in the diagnosis and treatment of tumors","volume":"12","author":"Lamberts","year":"1991","journal-title":"Endocrine Rev."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB60","first-page":"111P","article-title":"A new 99mTc-tricarbonyl bombesin analog with minimal abdominal accumulation and high target\/non-target ratios","volume":"42","author":"Lin","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB61","first-page":"13","article-title":"Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy","volume":"36","author":"Lipp","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB62","first-page":"222","article-title":"Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas","volume":"42","author":"Lugtenburg","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0969-8051(96)00068-6","article-title":"Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms","volume":"23","author":"McAfee","year":"1996","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB64","first-page":"94","article-title":"In situ radiotherapy with 111In-pentetreotide","volume":"4","author":"McCarthy","year":"1998","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB65","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB66","unstructured":"McGilvery, R.W., 1983. Biochemistry: A Functional Approach, 3rd Edition. W.B. Saunders, Philadelphia, pp. 341\u2013354."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB67","unstructured":"NeoTect, 1999. Package insert. Diatide, Londonderry."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB68","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/bjc.1998.101","article-title":"Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours","volume":"77","author":"Nilsson","year":"1998","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB69","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/0959-8049(94)00351-5","article-title":"Somatostatin receptor expression in lung cancer","volume":"30A","author":"O\u2019Byrne","year":"1994","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB70","unstructured":"OctreoScan, 1994. Package insert. Mallinckrodt, St Louis."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB71","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/00006231-199912000-00002","article-title":"Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals. An overview","volume":"20","author":"Okarvi","year":"1999","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB72","unstructured":"OncoScint, 1992. Package insert. Cytogen, Princeton."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB73","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s002590050122","article-title":"DOTATOC","volume":"24","author":"Otte","year":"1997","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/00006231-200006000-00014","article-title":"Receptor-mediated radiotherapy with 90Y-DOTATOC","volume":"21","author":"Paganelli","year":"2000","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB76","first-page":"36P","article-title":"Receptor mediated radiotherapy with 90Y-DOTATOC","volume":"42","author":"Paganelli","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB77","first-page":"452","article-title":"Thrombospondin analog Tc-99m-TP-1201 for imaging thrombosis","volume":"40","author":"Pallela","year":"1997","journal-title":"J. Lab. Comp. Radiopharm."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB78","first-page":"352","article-title":"99mTc-labeled vasoactive intestinal peptide receptor agonist. Functional studies","volume":"40","author":"Pallela","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB79","unstructured":"ProstaScint, 1996. Package insert. Cytogen, Princeton."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00006231-200102000-00013","article-title":"Different chelators and different peptides together influence the in vivo properties of 99Tcm","volume":"22","author":"Qu","year":"2001","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB81","first-page":"1480","article-title":"Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy","volume":"37","author":"Raderer","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB82","first-page":"1570","article-title":"Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer","volume":"39","author":"Raderer","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB83","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.2000.18.6.1331","article-title":"Value of peptide receptor scintigraphy using 123I-vasoactive intestinal peptide and 111In-DTPA-D-Phe1-octreotide in 194 carcinoid patients","volume":"18","author":"Raderer","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB84","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00006231-200011000-00013","article-title":"A receptor specific peptide for imaging infection and inflammation","volume":"21","author":"Rao","year":"2000","journal-title":"Nucl. Med. Comm."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB85","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0969-8051(01)00205-0","article-title":"99mTc labeled VIP analog","volume":"28","author":"Rao","year":"2001","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB86","first-page":"903","article-title":"A comparison of EGF and MAb528 labeled with 111In for imaging human breast cancer","volume":"41","author":"Reilly","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB87","first-page":"429","article-title":"111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR","volume":"41","author":"Reilly","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB88","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/bc00036a004","article-title":"A new radioligand for the epidermal growth factor receptor","volume":"6","author":"R\u00e9my","year":"1995","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB89","first-page":"1846","article-title":"In vitro identification of vasoactive intestinal peptide receptors in human tumors","volume":"36","author":"Reubi","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB90","first-page":"1825","article-title":"Neuropeptide receptors in health and disease. The molecular basis for in vivo imaging","volume":"36","author":"Reubi","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB91","first-page":"63","article-title":"Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"41","author":"Reubi","year":"1997","journal-title":"Q. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB92","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ijc.2910560513","article-title":"High density of somatostatin receptors in veins surrounding human cancer tissue","volume":"56","author":"Reubi","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB93","first-page":"1377","article-title":"Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors","volume":"57","author":"Reubi","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB94","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2265.2001.01056.x","article-title":"Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy","volume":"54","author":"Rhee","year":"2001","journal-title":"Clin. Endocrinology"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB95","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s002590050398","article-title":"Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-D-Phel-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue","volume":"26","author":"Rosch","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB96","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1399-3011.1997.tb01200.x","article-title":"Technetium-99m labeled epidermal growth factor-tumor imaging in mice","volume":"50","author":"Rusckowski","year":"1997","journal-title":"J. Pept. Res."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB97","first-page":"196","article-title":"Consequences of indium-111 decay in vivo","volume":"19","author":"Silvester","year":"1978","journal-title":"J. Lab. Comp. Radiopharm."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB98","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher\u2122","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB99","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.140.11.5136","article-title":"DOTA-lanreotide","volume":"140","author":"Smith-Jones","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB100","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/BF02426689","article-title":"Octreotide scintigraphy for small cell lung carcinona","volume":"21","author":"Stokkel","year":"1994","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB101","first-page":"111P","article-title":"In vitro evaluation of a 99mTc labeled RGD peptide as an antagonist of AVB3 integrins in tumors","volume":"42","author":"Su","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB102","first-page":"445","article-title":"Vapreotide labeled with Tc-99m for imaging tumors","volume":"9","author":"Thakur","year":"1996","journal-title":"Int. J. Oncol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB103","first-page":"107","article-title":"99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans","volume":"41","author":"Thakur","year":"2000","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1749-6632.2000.tb06949.x","article-title":"Imaging tumors in humans with Tc-99M-VIP","volume":"921","author":"Thakur","year":"2000","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB105","first-page":"1309","article-title":"111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung","volume":"42","author":"Traub","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB106","first-page":"1722","article-title":"Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies","volume":"42","author":"Van de Wiele","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB107","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0140-6736(94)92637-9","article-title":"Somatostatin-receptor scintigraphy in primary breast cancer","volume":"343","author":"van Eijck","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/S0969-8043(02)00192-6_BIB108","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1023\/A:1008302617988","article-title":"Somatostatin receptor imaging and therapy of pancreatic endocrine tumors","volume":"10","author":"van Eijck","year":"1999","journal-title":"Ann. Oncol."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB109","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM199410273311703","article-title":"Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors","volume":"331","author":"Virgolini","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB110","first-page":"1732","article-title":"Vasoactive intestinal peptide receptor scintigraphy","volume":"36","author":"Virgolini","year":"1995","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB111","first-page":"1850","article-title":"Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829","volume":"58","author":"Virgolini","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB112","first-page":"1928","article-title":"Indium-111-DOTA-Lanreotide","volume":"39","author":"Virgolini","year":"1998","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB113","first-page":"244P","article-title":"Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy","volume":"40","author":"Virgolini","year":"1999","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB114","first-page":"37P","article-title":"Improvement of life quality in patients with advanced neuroendocrine tumors after treatment with 200 MCI\/M2 90Y-DOTATOC","volume":"42","author":"Waldherr","year":"2001","journal-title":"J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB115","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","article-title":"Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma","volume":"27","author":"Wiseman","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/S0969-8043(02)00192-6_BIB116","first-page":"112","article-title":"The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma","volume":"65","author":"Wraight","year":"1992","journal-title":"Br. J. Cancer"}],"container-title":["Applied Radiation and Isotopes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804302001926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969804302001926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,7]],"date-time":"2020-03-07T10:36:57Z","timestamp":1583577417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969804302001926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["S0969804302001926"],"URL":"https:\/\/doi.org\/10.1016\/s0969-8043(02)00192-6","relation":{},"ISSN":["0969-8043"],"issn-type":[{"value":"0969-8043","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}